Sugi Predict

Sugi Predict / Compounds / SCHEMBL1385573

SCHEMBL1385573

SCHEMBL1385573

Nc1ccccc1S(=O)(=O)Nc1cnc2ccccc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.66
▸ CYP2C9 P11712 1/20 0.66
▸ ATIC P31939 1/20 0.51
▸ KMT2A Q03164 9/20 0.49
▸ MEN1 O00255 8/20 0.49
▸ NFKBIA P25963 2/20 0.49
▸ RELA Q04206 2/20 0.49
▸ SLC40A1 Q9NP59 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ PKM P14618 1/20 0.49
▸ POLB P06746 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ PDGFRB P09619 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5323047 0.90 LMNA (0.61) LMNACYP2C9ATICKMT2AMEN1
SCHEMBL9703752 0.83 PKM (0.54) LMNACYP2C9KMT2AMEN1NFKBIA
SCHEMBL3447749 0.82 ALDH1A1 (0.59) LMNACYP2C9ATICKMT2AMEN1
Sulfaquinoxaline SCHEMBL29391090 0.79 LMNA (1.00) LMNACYP2C9ATICKMT2AMEN1
Sulfaquinoxaline SCHEMBL4435622 0.79 LMNA (1.00) LMNACYP2C9ATICKMT2AMEN1
Sulfaquinoxaline SCHEMBL93789 0.79 LMNA (1.00) LMNACYP2C9ATICKMT2AMEN1
SCHEMBL30517293 0.78 LMNA (0.78) LMNACYP2C9ATICKMT2AMEN1
SCHEMBL1414326 0.78 LMNA (0.78) LMNACYP2C9ATICKMT2AMEN1
Sulfaquinoxaline SCHEMBL301314 0.78 LMNA (0.97) LMNACYP2C9ATICKMT2AMEN1
Sulfaquinoxaline SCHEMBL27961007 0.78 LMNA (0.97) LMNACYP2C9ATICKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4818110-B2 — — 2011-11-16 — — JP claimed
US-7947833-B2 methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 — — US claimed
US-7563895-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2009-07-21 — — US claimed
EP-1651621-B1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2008-08-06 — — EP claimed
US-20080103300-A1 PREPARATION OF QUINOXALINE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-05-01 — — US claimed
US-20080076918-A1 QUINOXALINE COMPOUNDS ALLISON BRETT D 2008-03-27 — — US claimed
US-7304051-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-04 — — US claimed
US-7288651-B2 Preparation of quinoxaline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-10-30 — — US claimed
EP-1651622-B1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2007-02-07 — — EP claimed
EP-1651621-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-03 — — EP claimed
EP-1651622-A1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS Janssen Pharmaceutica N.V. (BE) 2006-05-03 — — EP claimed
US-20050043310-A1 Preparation of quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — US claimed
WO-2005016897-A1 PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — WO claimed
WO-2005016896-A1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-24 — — WO claimed
US-20050038032-A1 Quinoxaline compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 — — US claimed
US-7947833-B2 methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 — — US disclosed
US-7947833-B2 methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation JANSSEN PHARMACEUTICA NV (BE) 2011-05-24 — — US disclosed
US-4015016-A [(2-Alkoxyberzylidine)amino]quanidines and their anticoccidal use THE DOW CHEMICAL COMPANY (US) 1977-03-29 — — US disclosed
US-3973039-A [(2-Alkoxybenzylidine)amino]guanidines and their anticoccidial use THE DOW CHEMICAL COMPANY (US) 1976-08-03 — — US disclosed
US-3769073-A PROCESS FOR PROTECTING A SUBSTRATE WITH AN ARYLSULFONAMIDOPYRAZINE INTUMESCENT AGENT CITIES SERVICE CO 1973-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103300-A1 PREPARATION OF QUINOXALINE COMPOUNDS CCKAR, CCKBR, GIPR LMNA 2703/4885CYP2C9 1205/4885ATIC 2301/4885
US-20050043310-A1 Preparation of quinoxaline compounds CCKAR, CCKBR, GIPR LMNA 2703/4885CYP2C9 1205/4885ATIC 2301/4885
US-20050038032-A1 Quinoxaline compounds CCKAR, CCKBR, GIPR LMNA 4073/4885CYP2C9 3415/4885ATIC 4018/4885
US-20080076918-A1 QUINOXALINE COMPOUNDS CCKAR, CCKBR, GIPR LMNA 4073/4885CYP2C9 3415/4885ATIC 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.